“Cannabidiol (CBD), one of the major products of the marijuana plant, is devoid of marijuana’s typical psychological effects. In contrast, potential antipsychotic efficacy has been suggested based on preclinical and clinical data.
In this report, we further investigated the efficacy and safety of CBD monotherapy in three patients with treatment-resistant schizophrenia (TRS).
Efficacy, tolerability and side effects were assessed.
All patients tolerated CBD very well and no side effects were reported.
These preliminary data suggest that CBD monotherapy may not be effective for TRS.”